DMRA — Damora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1800315 ·
Last close
$30.31
Market Cap
$1.87B
52W High
$34.89
52W Low
$18.59
ADV30
394,131
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -30,811,000 | -27,783,000 | 535,442,000 | 532,899,000 | 23,839,000 |
| Dec 2025 | 0 | — | -201,696,000 | -200,736,000 | 260,527,000 | 257,624,000 | 20,147,000 |
| Sep 2025 | 0 | — | -3,156,000 | -3,133,000 | 10,736,000 | 7,606,000 | 2,729,000 |
| Jun 2025 | 0 | — | -3,421,000 | -3,437,000 | 13,691,000 | 10,211,000 | 2,738,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-24,885,000
Investing CF
$-17,374,000
Financing CF
$295,921,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.50
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-515,146,000
Inventory
—
Receivables
$894,000
ST Investments
$0
EBIT TTM
$-239,084,000
Pretax Income TTM
$-234,999,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -210,872,000 | -209,839,000 | 260,527,000 | 20,147,000 | — | -6,726,000 |
| Dec 2024 | 0 | -21,292,000 | -21,439,000 | 17,132,000 | 1,301,000 | — | -18,623,000 |
| Dec 2023 | 0 | -36,457,000 | -38,349,000 | 38,227,000 | 5,896,000 | — | -36,911,000 |
| Dec 2022 | 0 | -61,207,000 | -61,624,000 | 73,188,000 | 11,435,000 | — | -42,932,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HMDCF | HUTCHMED (China) Ltd | $1.88B | $2.16 | — |
| SEPN | Septerna, Inc. | $1.89B | $40.52 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.84B | $64.43 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.92B | $18.13 | — |
| GHRS | GH Research PLC | $1.93B | $28.10 | — |
News headlines (Yahoo Finance, 1h cache)
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-10 20:05 · Yahoo
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 20:01 · Yahoo
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
2026-04-20 16:00 · Yahoo
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%
2026-04-10 13:55 · Yahoo
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
2026-08-05 12:00 · Yahoo
Damora Announces Redomestication from Delaware to Cayman Islands
2026-07-17 12:00 · Yahoo
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-12 20:05 · Yahoo
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
2026-05-08 21:30 · Yahoo
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
2026-05-05 17:05 · Yahoo
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum
2026-05-05 14:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.